Leuprolide Hexal 5 5.2MG IMPLANT
PDF Leaflet Revision Date: 06 April 2017
Clinical Summary
Quick overview from the medicine insert
Indication
Advanced hormone-dependent prostate carcinoma.
Dosage (summary)
Single dose every 12 weeks, subcutaneously.
Onset of Action / Duration
Onset: 2-3 weeks, Duration: up to 182 days.
Special Populations
- Patients with vertebral or cerebral metastases
- Diabetes mellitus
Pregnancy & Breastfeeding
Not indicated for use in females.
Contraindications
- Hypersensitivity to leuprorelin or GnRH analogues
- Hormone-independent carcinomas
Common side effects
- Urinary tract infections
- Decreased libido
- Hot flushes
- Nausea
- Erectile dysfunction
Counselling Points
- Monitor PSA and testosterone levels
- Inform about potential side effects
- Advise on driving and machinery use due to fatigue
Serious warnings
- Initial testosterone rise may exacerbate symptoms
- Monitor for spinal cord compression
Important Disclaimer
The Leuprolide Hexal 5 5.2MG IMPLANT professional information leaflet below is the property of Sandoz South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
